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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
beta-palmitate and contribution to softening of stools pursuant to 
Article 14 of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for authorisation of a 
health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of France, the 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to beta-palmitate and contribution to softening of stools. The 
food constituent, beta-palmitate, that is the subject of the health claim, is sufficiently characterised. Contribution 
to softening of stools is a beneficial physiological effect for infants. In weighing the evidence the Panel took into 
account that, out of two human intervention studies with important methodological limitations, one suggested a 
stool-softening effect of beta-palmitate whereas the second did not, that one animal study did not support a 
stool-softening effect of beta-palmitate, and that the evidence provided for a mechanism by which beta-palmitate 
could contribute to the softening of stools is weak. The Panel concludes that a cause and effect relationship has 
not been established between the consumption of beta-palmitate and softening of stools. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for 
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the 
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to 
beta-palmitate and contribution to softening of stools. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
The food constituent that is the subject of the health claim is beta-palmitate, a structured triglyceride 
with ≥ 50 % of palmitic acid at the sn-2 (middle or beta) position of the glycerol backbone. The 
intended use of beta-palmitate is to partially replace conventional triglycerides from vegetable oils in 
infant formulae to the extent that at least 35 % of the total palmitic acid content, which is assumed to 
be 20–25 % of total fatty acids, is in the sn-2 position. The Panel considers that beta-palmitate is 
sufficiently characterised. 
The claimed effect proposed by the applicant is “contributes to soften the stools, which helps to 
increase their frequency”. The target population proposed by the applicant is infants (from birth to 12 
months of age). Upon a request by EFSA for clarification on the claimed effect, the applicant 
indicated that the claimed effect referred to stool consistency rather than to stool frequency. 
Contribution to softening of stools is a beneficial physiological effect for infants.  
Eighteen publications were identified by the applicant and one by the Panel as being pertinent to the 
claim. Of these, three human studies and four non-human studies did not report on stool outcomes, 
and three human studies did not provide information about the effect of beta-palmitate on stool 
consistency. The Panel considers that no conclusions could be drawn from these publications for the 
scientific substantiation of the claim.   
Three human studies reported on the effects of beta-palmitate on stool consistency. In one study, stool 
consistency was an unplanned observation, which did not allow conclusions to be drawn from that 
study on stool consistency for the scientific substantiation of the claim.  
In a 12-week intervention study, the consumption of a formula containing 50 % of palmitate in the 
sn-2 position significantly increased the percentage of soft (runny/watery) stools compared with 
consumption of a formula with only 12 % of palmitate in the sn-2 position; the volume and frequency 
of stools were not different between the two formula groups. The effect on stool consistency with the 
beta-palmitate formula disappeared when solid complementary foods were added to the formula diet. 
This study was affected by a high drop-out rate, a high rate of non-compliance, and results were 
provided for completers only, without taking into account repeated measures. The Panel considers 
that this study with important methodological limitations suggests an effect of beta-palmitate in 
formula on softening of stools.  
Another 12-week human intervention study found no difference in the consistency of stools between 
two groups of infants fed formulae with 44 % and 14 % of palmitate in the sn-2 position, respectively. 
The Panel considers that this study with important methodological limitations (i.e. high drop-out rate, 
analysis performed in completers without taking into account repeated measures or multiple 
comparisons) suggests no effect of beta-palmitate in formula on softening of stools. 
In weighing the evidence the Panel took into account that, out of two human intervention studies with 
important methodological limitations, one suggested a stool-softening effect of beta-palmitate 
whereas the second did not, that one animal study did not support a stool-softening effect of 
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beta-palmitate, and that the evidence provided for a mechanism by which beta-palmitate could 
contribute to the softening of stools is weak.    
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of beta-palmitate and softening of stools. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 14/02/2008. 
 The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
 On 26/03/2008, during the validation process of the application, EFSA sent a request to the 
applicant asking it to provide missing information. 
 On 01/07/2013, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 18/07/2013. 
 On 25/09/2013, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The clock 
was stopped on 04/10/2013 and was restarted on 24/10/2013, in compliance with Article 
16(1) of Regulation (EC) No 1924/2006. 
 On 24/10/2013, EFSA received the requested information. 
 During its meeting on 06/02/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to beta-palmitate 
and contribution to softening of stools. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: beta-palmitate and contribution to 
softening of stools. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of beta-palmitate, a positive assessment of its safety, nor a decision on whether 
                                                     
 
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
Beta-palmitate and contribution to softening of stools  
 
 
EFSA Journal 2014;12(2):3578             6 
beta-palmitate is, or is not, classified as a foodstuff. It should be noted that such an assessment is not 
foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Specialised Nutrition Europe (formerly IDACE), 9-31, Avenue des 
Nerviens 1040, Brussels, Belgium. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent for which the claim is made is beta-palmitate. 
Health relationship as claimed by the applicant 
According to the applicant, beta-palmitate contributes to soften the stools, which helps to increase 
their frequency in infants receiving a formula enriched with this lipid source. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Beta-palmitate enrichment 
contributes to soften stool consistency which helps to increase their frequency”. 
As equivalent alternative wordings, the applicant has also proposed: “Beta-palmitate contributes to 
soften stool consistency/contributes to increase stool frequency/is suitable to soften stool 
consistency/suitable to increase stool frequency”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is infants (from birth to 12 months of age) as defined 
in Directive 89/398/EEC on foodstuffs intended for particular nutritional uses, especially infant 
formulas as defined by 2006/141/EC, for which authorised claims and conditions of use are already 
fixed by the Annex IV of this directive, the follow-on formulas and the Foods for Special Medical 
Purposes (FSMP) as defined by Directive 1999/21/EC.  
According to the applicant, in formulas supported by this claim, beta-palmitate will account for a 
minimum of 35 % of total palmitic acid when the palmitic acid content is between 20 and 25 % of 
total fatty acids.  
ASSESSMENT 
1. Characterisation of the food/constituent  
The food constituent that is the subject of the health claim is beta-palmitate.  
Beta-palmitate is a structured triglyceride mixture with a high content of triglycerides esterified with 
palmitic acid at the sn-2 (middle or beta) position of the glycerol backbone. Beta-palmitate is 
produced by enzymatic esterification of unnamed vegetable oils after which 45 to 80 % of total 
palmitic acid are esterified at the sn-2 position. The sn-1 and sn-3 positions are predominantly 
occupied by unsaturated fatty acids, primarily oleic acid (C18:1). The main triglycerides present in 
beta-palmitate are 1,2-dipalmitoyl-3-oleyl triglyceride and 1,3-dioleyl-2-palmitoyl triglyceride. 
According to the specifications from two manufacturers, beta-palmitate contains > 98 % triglycerides; 
28–60 % of total fatty acids are palmitic acid of which ≥ 50 % in the sn-2 position, 30–60 % are oleic 
acid, < 2 % are trans-fatty acids while < 0.1 % are free fatty acids. The peroxide value is 
≤ 2.0 mEq O2/kg. The ratio of saturated fatty acids (SFAs) to mono-unsaturated fatty acids and to 
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poly-unsaturated fatty acids measured in batches of beta-palmitate was 40–50: 45–50 : 5–7. 
Beta-palmitate is stabilised using antioxidants suitable for use in infant formula in the EU. 
The intended use of beta-palmitate is to partially replace conventional triglycerides from vegetable 
oils in infant formulae to the extent that at least 35 % of the total palmitic acid content, which is 
assumed to be 20–25 % of total fatty acids, is in the sn-2 position, which means that the amount of 
beta-palmitate used in a formula would depend on both the total fat content and its fatty acid 
composition. 
The fatty acid content and the positioning of fatty acids on the glycerol backbone can be measured by 
established methods. 
The Panel notes that the term “beta-palmitate” is used in the application to denote both the structured 
triglyceride mixture with palmitate predominant at the sn-2 position of the glycerol backbone and the 
palmitate monoglyceride arising from digestion by lipases. In this opinion the term beta-palmitate will 
be used only for the structured triglyceride mixture, which is the subject of the health claim.  
The Panel considers that the food constituent, beta-palmitate, which is the subject of the health claim, 
is sufficiently characterised.  
2. Relevance of the claimed effect to human health  
The claimed effect proposed by the applicant is “contributes to soften the stools, which helps to 
increase their frequency”. The target population proposed by the applicant is infants (from birth to 
12 months of age). Upon a request by EFSA for clarification of the claimed effect, the applicant 
indicated that the claimed effect referred to stool consistency rather than to stool frequency. 
Hard stools resulting from colonic retention, decreased propulsion and dehydration of intestinal 
contents is the predominant symptom of constipation in infants. 
The Panel considers that contribution to softening of stools is a beneficial physiological effect for 
infants.  
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in Medline based on unspecified search criteria to identify 
publications which evaluated the effects of beta-palmitate in infants and young children. Studies 
carried out with other lipid constituents or in other population groups were excluded. The period 
which was covered by the literature search was not specified. 
The applicant identified 18 references as pertinent to the claim. One systematic review which 
addressed the effects of formulae with different lipid structures on calcium absorption and bone 
mineralisation (Koo et al., 2006) and two intervention studies which investigated the effects of 
beta-palmitate on the absorption of lipids and on the structure of plasma lipids in infants (Innis et al., 
1994; Nelson and Innis, 1999) did not report on stool outcomes. The Panel considers that no 
conclusions can be drawn from these publications for the scientific substantiation of the claim.    
Of the remaining references, six referred to human (Carnielli et al., 1996; Kennedy et al., 1999; Miró 
et al., 2001; Bongers et al., 2007; Chevallier et al., 2009) and animal (Enzymotec, unpublished) 
intervention studies conducted with beta-palmitate and which report on stool consistency, whereas 
four human studies (Quinlan et al., 1995; Carnielli et al, 1995; Lucas et al., 1997; Lopez-Lopez et al., 
2001) and five non-human studies (de Fouw et al., 1994; Innis et al., 1997; Innis and Dyer, 1997; Lien 
at al., 1997; Sanders at al., 2001) addressed the mechanisms by which beta-palmitate could exert the 
claimed effect.  
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3.1. Studies on stool consistency 
Five human intervention studies reported on stool consistency as an outcome. One study was a 
single-arm intervention with no control group (Chevallier et al., 2009); the composition of the control 
formula was not specified in another study (Miró et al., 2001, unpublished); and in a third study 
(Bongers et al., 2007) the intervention and control formulas did not differ only in their beta-palmitate 
content, but also in the content of other ingredients (e.g. galacto-oligosaccharides and long-chain 
fructo-oligosaccharides), which may have an effect on stool consistency. The Panel notes that these 
studies do not provide information about the effect of beta-palmitate on stool consistency and 
considers that no conclusions can be drawn from these studies for the scientific substantiation of the 
claim. 
One intervention study investigated the effects of beta-palmitate on stool consistency in healthy 
infants (Kennedy et al., 1999). A second intervention study, which addressed the effects of 
beta-palmitate on the intestinal absorption and faecal excretion of calcium and fatty acids, reported on 
stool consistency as an unplanned observation (Carnielli et al., 1996). The Panel is aware of one 
additional study by Litmanovitz et al. (2013; 2013-unpublished) which investigated the effects of 
beta-palmitate on bone health and reported on stool consistency as a secondary outcome. 
The study by Carnielli et al. (1996) was a balance study designed to investigate the effect of the 
structural position of palmitic acid in the triglyceride on the intestinal absorption and the faecal 
excretion of fat and calcium. Data on stool consistency were collected when differences in the first 
faecal samples were noted, but systematic scoring of the degree of stool hardness and colour was not 
part of the original protocol and was not undertaken for all subjects. The Panel considers that no 
conclusions can be drawn from this unplanned observation for the scientific substantiation of the 
claim.  
Kennedy et al. (1999) conducted a randomised, double-blind, controlled, parallel intervention study to 
investigate the effects of beta-palmitate on skeletal mineral deposition and stool consistency in 
203 formula-fed healthy term-born infants (119 males). Subjects were enrolled within the first eight 
days of life and randomised to receive either a formula with beta-palmitate (n = 100) or a control 
formula without beta-palmitate (n = 103) for 12 weeks. One hundred and twenty breast-fed infants 
were also studied from 10 to 12 weeks of age (reference group). The beta-palmitate and control 
formulae were similar in percentage of fatty acids as palmitic acid (about 20 %), but differed in the 
percentage of palmitate in the sn-2 position (50 % in the beta-palmitate formula vs. 12 % in the 
control formula). The beta-palmitate formula also had a 4 % higher energy and 7 % higher fat content 
than the control formula. Sample size calculations (120 per group) were based on differences in stool 
hardness and constipation between the groups at 5 % significance and 80 % power. 
Stool consistency, frequency and volume were reported by mothers of formula-fed infants in 7-day 
diaries at 6 and 12 weeks. Each stool passed by an infant was coded for consistency and volume by 
using previously validated colour photos for stool consistency (runny, mushy, formed, or hard) and 
diagrams for stool volume. Mothers of breast-fed infants completed the stool diary and questionnaire 
at 12 weeks only. Differences in stool consistency (per cent of subjects with hard or formed stools, 
with mushy stools, and with runny or watery stools) and in the stool consistency score between the 
beta-palmitate formula and the control formula at weeks 6 and 12 were analysed using the Mann-
Whitney U-test. The Kruskal–Wallis test was used to assess differences in these variables among the 
three study groups at week 12. Analysis of variance was used to examine differences in total stool 
volume per week and volume per stool among the three groups with post-hoc pairwise comparisons 
by Bonferroni tests. The Panel notes that repeated measures were not taken into account in data 
analyses. 
Twenty infants in the beta-palmitate group and 23 infants in the control-formula group stopped 
receiving the study formula before the end of week 12 because of “hunger”, severe constipation (two 
in the beta-palmitate and one in the control formula group), vomiting and unknown reasons. Of the 
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80 infants in both formula groups who completed 12 weeks of study formula feeding, 20 infants in the 
beta-palmitate group and 17 in the control formula group (together > 20%) received complementary 
food at a median age of 10 weeks, leaving 60 infants in the beta-palmitate group and 63 infants in the 
control formula group who were exclusively fed with either study formula for 12 weeks (a total of 
61 % of the randomised infants). Data on stool consistency, volume and frequency were analysed for 
84 and 75 infants in the beta-palmitate group and for 87 and 73 infants in the control formula group at 
weeks 6 and 12, respectively. No intention-to-treat analyses were performed. Upon a request by EFSA 
for clarification of the number of infants included in the statistical analyses, the applicant indicated 
that data on stool characteristics at 12 weeks were available for only 75 and 73 infants out of the 
80 infants per group who completed the 12 weeks of formula feeding.  
Infants consuming the beta-palmitate formula passed a significantly higher percentage of 
runny/watery stools than infants consuming the control formula at six [median (interquartile 
range) = 14 (0, 50) and 0 (0, 0), respectively] and 12 weeks [7 (0,29) and (0, 0), respectively], and a 
significantly lower percentage of hard or formed stools at week 6 [0 (0, 35) and 33 (0, 73), 
respectively]. No significant differences between the two formula groups were observed for the 
percentage of hard or formed stools at week 12, or for the percentage of mushy stools at any time 
point. Differences in stool consistency between the formula groups were no longer significant, 
however, when infants received solids in addition to formula. Breast-fed infants passed significantly 
lower percentages of hard/formed and mushy stools and a significantly higher percentage of 
runny/watery stools than either formula group. There were no differences between the formula groups 
in the number of stools per week or the mothers’ estimation of total stool volume per week or volume 
per stool.  
The Panel notes that in this intervention trial of 12 weeks’ duration conducted in healthy term infants, 
consumption of a formula in which 50 % of the palmitic acid is esterified to the sn-2 position of the 
glycerol backbone increased the percentage of soft (runny/watery) stools compared with consumption 
of a formula with the same palmitic acid content but with only 12 % in the sn-2 position, and that 
volume and frequency of stools were not different between the two formula groups. The effect on 
stool consistency with the beta-palmitate formula disappeared when solid complementary foods were 
added to the formula diet. The Panel also notes that this study was affected by a high drop-out rate 
(20 %) and a high rate of non-compliance (39 %), that results were provided for completers only (i.e. 
subjects who received the study formula during 12 weeks and provided complete data sets), and that 
repeated measures were not taken into account in data analysis.  
The Panel considers that this study with important methodological limitations suggests a stool 
softening effect of a formula containing 20 % of fatty acids as palmitic acid and 50 % of palmitate in 
the sn-2 position compared with a similar formula with only 12 % of palmitate in the sn-2 position.  
A randomised, double-blind, controlled, parallel intervention study by Litmanovitz et al. (2013; 2013, 
unpublished) enrolled 83 healthy, term-born infants within the first two weeks of life. Formula-fed 
infants (n = 58) were randomised to receive either a formula with beta-palmitate (44 % of total 
palmitic acid in the sn-2 position of the glycerol backbone, n = 30) or a regular formula (14 % of total 
palmitic acid in the sn-2 position, n = 28) for 12 weeks. The composition of the two formulas was 
similar (about 20 % of fatty acids as palmitic acid) except for the percentage of palmitate in the sn-2 
position. A reference group of infants exclusively breast-fed (n = 25) was also included in the study. 
The primary outcome (used for power calculations) was changes in bone speed of sound (Litmanovitz 
et al., 2013). Secondary outcomes were “infant comfort”, crying patterns and stool consistency 
(Litmanovitz et al., 2013, unpublished).  
Parents filled in three-day reports prior to the clinical visits (at baseline, and 6 and 12 weeks) on 
crying patterns, behaviour, formula consumption and stool characteristics, including colour (yellow, 
green, brown, black) and consistency (hard, mushy, watery). Statistical analyses were conducted using 
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pairwise t-tests for scale outcomes and pairwise chi-square tests for nominal outcomes for 
comparisons between the formula groups and between the formula groups and the breast-fed group.  
Stool diaries were available from 61 infants (73 % of enrolled infants) after 12 weeks (beta-palmitate 
formula, n = 21; regular formula, n = 21; breast-fed, n = 19). Stool frequency was significantly higher 
and stool consistency significantly lower (p < 0.05) in the breast-fed infants compared to the formula 
groups at both 6 and 12 weeks, but was not significantly different between the two formula groups. At 
six weeks, hard stools were reported for 23.1 %, 16.7 %, and 5.0 % of infants consuming the 
beta-palmitate formula, the regular formula, and breast milk, respectively, whereas the percentage of 
infants with hard stools at 12 weeks was 14.3 %, 23.8 %, and 0.0 % for the beta-palmitate formula, 
the regular formula, and breast milk groups, respectively. No significant differences between groups 
were observed at six weeks. At 12 weeks, the percentage of infants with hard stools was significantly 
higher in the regular formula group than in the breast-fed group (p < 0.05), whereas no significant 
differences were observed between the beta-palmitate formula group and the breast-fed group or 
between the two formula groups. 
The Panel notes that this controlled randomised trial of 12 weeks’ duration found no difference in the 
consistency of stools between two groups of infants fed formulae with 44 % and 14 % of the palmitic 
acid content in the sn-2 position of the glycerol backbone, respectively. The Panel also notes that this 
study was affected by a high drop-out rate (28 %, reasons not specified) and that the results were 
analysed in completers only without taking into account repeated measures or multiple comparisons. 
The Panel considers that this study with important methodological limitations suggests no stool 
softening effect of a formula containing 44 % of palmitate in the sn-2 position compared with a 
similar formula with 14 % of palmitate in the sn-2 position. 
An animal study conducted in rats reported on stool consistency (Enzymotec, unpublished). A total of 
100 rats (25 per group) were assigned to consume for three days a fat-free (control) diet or one of 
three diets containing 22 % of palmitic acid, of which 20 %, 40 % or 50 % was in the sn-2 position, 
but otherwise comparable regarding nutrient composition and fatty acid profile. No significant 
differences were observed among the three groups fed the fat-containing diets regarding stool 
consistency or faecal weight. The Panel considers that this study does not support a stool softening 
effect of beta-palmitate. 
The Panel notes that one human intervention study reported stool-softening effects of a formula 
containing 50 % of palmitate in the sn-2 position compared with a formula containing 12 % only with 
exclusive formula feeding and only in infants  2 weeks of age at baseline (Kennedy et al., 1999), 
whereas another human intervention study reported no stool-softening effects of a formula containing 
44 % of palmitate in the sn-2 position compared with a formula containing 14 % and one animal study 
did not support a stool-softening effect of beta-palmitate. The Panel also notes that the two human 
intervention studies from which conclusions could be drawn with respect to the effects of beta-
palmitate on stool consistency suffer from important methodological limitations and are at high risk of 
bias.  
3.2. Studies on mechanisms by which beta-palmitate could exert the claimed effect 
Regarding the mechanism by which beta-palmitate could exert the claimed effect, the applicant claims 
that stool consistency correlates with the amount of calcium soaps (salts) in the stools, which are 
formed in the gut from unabsorbed calcium and SFAs and are solid at body temperature. An increased 
absorption of dietary calcium and/or of SFAs (including palmitic acid) would decrease the formation 
of calcium soaps in the gut and, thus, the consistency of stools. The applicant indicates that palmitate 
in the sn-2 position is more readily hydrolysed and absorbed in the gut than palmitate in the extreme 
positions of the glycerol backbone.  
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A claim on beta-palmitate and increased calcium absorption in infants has been already evaluated by 
the Panel with a negative outcome (EFSA NDA Panel, 2011). In that opinion, the Panel evaluated the 
studies by Carnielli et al. (1995, 1996) and by Lucas et al. (1997) and noted that one short-term 
human intervention study in term newborn infants (Carnielli et al., 1996) provided evidence that a 
high degree of palmitate in the sn-2 position could increase calcium absorption and decrease faecal fat 
and calcium excretion, whilst two other studies in pre-term infants did not show an effect on calcium 
absorption but rather on faecal calcium excretion as calcium soaps (Carnielli et al., 1995; Lucas et al., 
1997).  
In addition, three human studies have been provided by the applicant in relation to the mechanism by 
which beta-palmitate could exert an effect on stool consistency (Quinlan et al., 1995; Kennedy et al., 
1999; Lopez-Lopez, 2001).  
One observational study in breast-fed infants and formula-fed infants reported a significant 
relationship between stool hardness and the content of calcium and of calcium fatty acid soaps in the 
faeces (Quinlan et al., 1995). In the study by Kennedy et al. (1999) described above, total fatty acids 
and SFA soaps in faeces were significantly lower in the beta-palmitate formula group than in the 
control group. In the study by Lopez-Lopez et al. (2001), fatty acids and palmitic acid in faeces, but 
not faecal calcium, were significantly lower in infants consuming a formula with 45 % of palmitic 
acid in the sn-2 position compared to a formula with 19 % in the sn-2 position.   
Out of the six animal studies provided by the applicant, only two conducted in rats reported on the 
composition of stools following consumption of beta-palmitate (Lien et al., 1997; Enzymotec, 
unpublished). Both studies showed an inverse relationship between the amount of palmitate in the 
triglyceride sn-2 position in the animal’s diet and faecal excretion of fatty acids (including palmitic 
acid) and fatty acid soaps. However, lower faecal excretion of SFAs and fatty acid soaps following 
consumption of diets with high percentages of palmitate in the sn-2 position did not result in softer 
stools in the only study which investigated this outcome (Enzymotec, unpublished).  
The Panel considers that the evidence provided for a mechanism by which beta-palmitate could 
contribute to the softening of stools is weak.   
In weighing the evidence the Panel took into account that, out of two human intervention studies with 
important methodological limitations, one suggested a stool-softening effect of beta-palmitate 
whereas the second did not, that one animal study did not support a stool-softening effect of 
beta-palmitate, and that the evidence provided for a mechanism by which beta-palmitate could 
contribute to the softening of stools is weak.    
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of beta-palmitate and softening of stools. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, beta-palmitate, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect proposed by the applicant is “contributes to soften the stools, which helps 
to increase their frequency”. The target population proposed by the applicant is infants (from 
birth to 12 months of age). Contribution to softening of stools is a beneficial physiological 
effect for infants.  
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 A cause and effect relationship has not been established between the consumption of 
beta-palmitate and softening of stools.  
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on beta-palmitate and contribution to softening of stools pursuant to Article 
14 of Regulation (EC) No 1924/2006 (Claim serial No: 0094_FR). February 2008. Submitted by 
Specialised Nutrition Europe (formerly IDACE). 
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ABBREVIATIONS 
SFAs  Saturated fatty acids 
